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PMH4
CLINICAL, HUMANISTIC, AND ECONOMIC 
OUTCOMES ASSOCIATED WITH LONG-TERM 
TREATMENT OF MANIA WITH OLANZAPINE
Namjoshi M, Edgell ET, Feldman PD, Sanger TM, Tohen MF, 
Breier A
Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN, USA
OBJECTIVE: To determine the clinical, humanistic, and
economic outcomes associated with olanzapine in the
treatment of mania. METHODS: Patients with Bipolar I
Disorder and a confirmed diagnosis of mania were ran-
domized to either olanzapine (5–20mg) or placebo for 3
weeks. The acute phase was followed by a 49-week open
label extension phase in which all patients were treated
with olanzapine. The Young Mania Rating Scale (Y-MRS)
and the Medical Outcomes Study Short Form 36 (SF-36)
were used to assess changes in clinical and humanistic
outcomes, respectively. Health care resource use data
was collected and corresponding costs calculated for the
extension. RESULTS: During the acute phase, the olan-
zapine treatment group experienced a statistically signifi-
cant (P  0.02) mean improvement from baseline in the
YMRS total score compared to placebo. Olanzapine-
treated patients also experienced a statistically significant
(P  .001) mean improvement in clinical symptoms over
the extension. Health-related quality of life improvements
were seen in several dimensions both in the 3-week acute
phase and the extension. Statistically significant differ-
ences in the SF-36 dimensions of bodily pain (P  .001),
general health (P  .009), role emotional (P  .03), and
social functioning (P  .004) were seen in the extension.
In the 52 weeks prior to the study, patients spent an aver-
age of 4.1% of their time hospitalized compared with
only 1.3% of their time during the extension. This reduc-
tion led to a mean total cost savings of almost $900 per
month during the extension compared with the 52 weeks
prior to the study. CONCLUSION: Olanzapine had a posi-
tive impact on the clinical, humanistic, and economic
outcomes in patients with mania, and may be a cost-
effective treatment option in this population.
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OBJECTIVES: Describe reasons for and economic conse-
quences of a switch from various antipsychotics to amisul-
pride in 150 schizophrenic patients. METHOD: Multi-
centre in a “real life” setting study over a 2-year period
(Switch  D0;  365 days). Data are collected from hos-
pital records of patients switched from various antipsy-
chotics to amisulpride between January 1997, and Febru-
ary 1999. Change in hospitalization is analyzed using 2
hypothesis, partition at D0, and partition at W6 (hospi-
talizations during the first 6 weeks of amisulpride are at-
tributed to failure of previous treatment and results adjusted
to one year). RESULTS: Socio-demographic characteristics
observed on the first 25 files suggest that the population
of the study does not differ from the general schizo-
phrenic population. Previous treatment (76% classical
antipsychotic, 12% atypical antipsychotic) was stopped
at D0. The reasons for the switch are lack of efficacy
(64%) and side effects (36%). Results show a decrease in
hospitalization after the switch. Partition at D0: 12
days for full time hospitalization, 38 for part time hos-
pitalization, 23 for part time night. Partition at W6: re-
spectively 38, 44 and 23 days. The maximum of
days hospitalized decreases after the switch from 338 to
187 for full time hospitalization, 365 to 208 for part time
day and from 62 to 31 for part time night. Outpatients
are more regularly followed after the switch:4 visits for
patients followed in community, 3 visits for patients
hospitalized at least one time. Initiated dose of amisul-
pride remains the same after one year. CONCLUSION:
Preliminary results show a trend for a decrease in hospi-
talization and an increase in outpatient visits. If this is
confirmed, it would mean that amisulpride is able to cut
the major cost of this disease and to improve the follow-
up of schizophrenic patients in community.
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OBJECTIVE: Investigate the relationship between ad-
verse events and health-related quality of life (HRQoL) in
patients receiving antipsychotics for schizophrenia. METH-
ODS: The analyses included a subset of patients from a
large 6-month, prospective, observational study of outpa-
tients receiving antipsychotics for schizophrenia. The
analyses included the most commonly (1%) recorded
adverse events. The HRQoL was evaluated using the EQ-
5D Index (EQ-I) and Visual Analog Scale (VAS). RE-
SULTS: The analyses included 2,128 olanzapine, 417 ris-
peridone, and 112 haloperidol treated patients. The most
common (1%) adverse events were: tremor, hypokine-
sia/akinesia, rigidity, akathesia, dystonia, dyskinesia, weight
gain, and somnolence. Compared to olanzapine-treated
patients, haloperidol-treated patients had significantly
higher incidences for 5 of the extrapyramidal symptoms
and risperidone-treated patients had significantly higher
incidences for 4 of the extrapyramidal symptoms. Ris-
peridone and haloperidol treated patients were signifi-
